Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | PIM1 | P11309 | 2/20 | 0.53 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.53 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.53 |
| ▸ | PRKACA | P17612 | 1/20 | 0.53 |
| ▸ | LTK | P29376 | 1/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.53 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.53 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.53 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.53 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.53 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25168740 | 0.89 | ADRA2A (0.51) | ABCG2EGFRPIM1RPS6KA3DAPK3 | |
| SCHEMBL34467229 | 0.88 | EGFR (0.56) | EGFRALDH1A1CYP3A4TSHRHSD17B10 | |
| SCHEMBL6175758 | 0.88 | EGFR (0.56) | EGFRALDH1A1CYP3A4TSHRHSD17B10 | |
| SCHEMBL3759489 | 0.87 | F12 (0.52) | EGFRAURKBALDH1A1CYP3A4FDPS | |
| SCHEMBL4497329 | 0.86 | ABCG2 (0.58) | ABCG2EGFRPIM1ALDH1A1TP53 | |
| SCHEMBL31098979 | 0.86 | TNF (0.57) | ABCG2EGFRALDH1A1HPGDFDPS | |
| SCHEMBL31098966 | 0.86 | TNF (0.57) | ABCG2EGFRERBB2TP53NPY5R | |
| SCHEMBL20356687 | 0.86 | NPC1 (0.56) | ABCG2EGFRLRRK2ALDH1A1HPGD | |
| SCHEMBL20852287 | 0.86 | EGFR (0.60) | ABCG2EGFRCLK4ALDH1A1HPGD | |
| SCHEMBL10000199 | 0.84 | KDR (0.56) | EGFRERBB2FDPSNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112390755-B | Heteroaryl method for amine | 中国科学院理化技术研究所 | 2024-08-02 | — | — | CN | claimed |
| US-9216964-B2 | Hedgehog pathway modulators | NOVARTIS AG (CH) | 2015-12-22 | — | — | US | disclosed |
| US-9115112-B2 | Aminoanthracene derivative and an organic electroluminescent element employing the same | DOOSAN CORPORATION (KR) | 2015-08-25 | — | — | US | disclosed |
| CN-102203067-B | Hedgehog pathway modulators | IRM LLC | 2014-01-15 | — | — | CN | disclosed |
| US-20130296333-A1 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2013-11-07 | — | — | US | disclosed |
| US-8507491-B2 | Compounds and compositions as hedgehog pathway inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-20120161615-A1 | AMINOANTHRACENE DERIVATIVE AND AN ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | DOOSAN CORPORATION (KR) | 2012-06-28 | — | — | US | disclosed |
| CN-102203067-A | Hedgehog pathway modulators | IRM LLC | 2011-09-28 | — | — | CN | disclosed |
| US-20110152282-A1 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2011-06-23 | — | — | US | disclosed |
| EP-2328871-A2 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010147318-A2 | AMINOANTHRACENE DERIVATIVE AND AN ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | 주식회사 두산 (KR) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010027746-A2 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2010-03-11 | — | — | WO | disclosed |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | LEXICON PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | LEXICON PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-RE36256-E | ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296333-A1 | HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | ABCG2 4107/4885EGFR 127/4885PIM1 2600/4885 |
| US-20110152282-A1 | HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | ABCG2 4472/4885EGFR 53/4885PIM1 2747/4885 |
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | TNF, IL6, CXCL8 | ABCG2 4326/4885EGFR 1259/4885PIM1 4649/4885 |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | CPT1B, CPT1A, SHBG | ABCG2 2597/4885EGFR 3860/4885PIM1 4541/4885 |
| US-20120161615-A1 | AMINOANTHRACENE DERIVATIVE AND AN ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | AADAT, ALAD, AAAS | ABCG2 1956/4885EGFR 791/4885PIM1 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.